Longevity InTime BioTech

AI Health Online Tracking Technology for prediction & prevention of severe diseases, aimed to prolong life on 20+ years

General Information
Company Name
Longevity InTime BioTech
Founded Year
2018
Location (Offices)
Wilmington, United States +1
Founders / Decision Makers
Number of Employees
22
Industries
AI, Digital Health, Health Care +4
Funding Stage
Pre Seed
Social Media

Longevity InTime BioTech - Company Profile

Longevity InTime BioTech is a pioneering startup committed to revolutionizing healthcare through its innovative technology. Leveraging 4P medicine, the company focuses on Predictive, Preventive, Personalized, and Participatory approaches to enable real-time early-stage disease diagnosis by collecting and analyzing human biodata online. With a strong emphasis on precision medicine, the company's technology suite, comprising wearable devices and Rapid Diagnostic Tests, is designed to identify and combat diseases at their nascent stages, ultimately impacting longevity. Longevity InTime™ aims to extend life expectancy by up to 30 years through the measurement of over 400 essential life parameters and the utilization of AI to forecast and prevent severe diseases. The company's machine learning algorithms are refined with over 70 years of human clinical trial data, meticulously curated from leading medical databases such as PubMed and Mimic. Currently, Longevity InTime™ is engaged in beta testing the BMI Disease Tracker on Google Play and AntiObesity on the App Store. These endeavors are complemented by the launch of an online self-checkup tracker available for download on the company's website, addressing global health challenges and providing users with additional perspectives on their health conditions. The company's team is a remarkable testament to diversity and talent, comprising 30 members from 12 different countries. Notably, they have successfully built one of the largest biotech startups without any salary expenses. In terms of investment, Longevity InTime™ secured a $100.00K Pre Seed Round investment on 22 January 2020, with Google Cloud as the lead investor. The company actively solicits support, citing Sequoia Capital's track record of early-stage investments and its participation in companies now valued at $3.3 trillion. This appeal draws parallels to Sequoia Capital's early investment in Apple back in 1978, emphasizing the potential for substantial growth and impact. In summary, Longevity InTime BioTech presents an ambitious vision, bolstered by cutting-edge technology, diverse talent, and strategic investment partnerships, positioning the company as a significant player in the healthcare and biotech sectors.

Taxonomy: Precision Medicine, Health Tech, Biotech, Wearable Devices, Rapid Diagnostic Tests, Predictive Analytics, Preventive Healthcare, Personalized Medicine, Participatory Medicine, Big Data Analytics, Clinical Trials, Mobile Health Apps, Global Health, Startup Investment

Funding Rounds & Investors of Longevity InTime BioTech (3)

View All
Funding Stage Amount No. Investors Investors Date
Pre Seed Round $100.00K 1 Google Cloud 22 Jan 2020
Pre Seed Round $2.25M 1 Oleg Teterin 01 Sep 2019
Pre Seed Round $50.00K 1 19 Sep 2018

Latest News of Longevity InTime BioTech

View All

No recent news or press coverage available for Longevity InTime BioTech.

Similar Companies to Longevity InTime BioTech

View All

No funding or investment information available for Longevity InTime BioTech at this time.